{"transactions":[{"id":1508595,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option","published_at":"2024-05-20T19:21:37.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0.53,"value":5300.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the reporting person on January 2, 2024, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024."}],"balance_after":33525,"derivative":{"exercise_price":0.53,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-063356","document":"tm2414962-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465924063356/tm2414962-2_4seq1.xml","form_type":"4"}},{"id":1888422,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T16:25:57.000Z","date":"2023-01-01","kind":"grant","planned":false,"acquired":true,"shares":125,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects shares of common stock issued to the Reporting Person upon vesting and settlement of restricted stock units (\"RSUs\") on March 31, 2023, which RSUs were awarded to the Reporting Person as of January 1, 2023, subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of common stock issued to the Reporting Person upon vesting and settlement of restricted stock units (\"RSUs\") on March 31, 2023, which RSUs were awarded to the Reporting Person as of January 1, 2023, subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were awarded as compensation to the Reporting Person for his service as a director of the Company."}],"balance_after":3250,"source":{"system":"sec-edgar","filing":"0001104659-23-061736","document":"tm2315065-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923061736/tm2315065-1_4seq1.xml","form_type":"4"}},{"id":2022256,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-11T00:42:27.000Z","date":"2022-10-01","kind":"grant","acquired":true,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares underlying certain restricted stock units (\"RSUs\"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the \"RSU Agreement\"). 625 RSUs vested in one installment on December 31, 2022 and were settled on January 3, 2023, subject to the terms and conditions set forth in the RSU Agreement and as a result, 625 shares of common stock were issued to the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying certain restricted stock units (\"RSUs\"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Issuer to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the \"RSU Agreement\"). 625 RSUs vested in one installment on December 31, 2022 and were settled on January 3, 2023, subject to the terms and conditions set forth in the RSU Agreement and as a result, 625 shares of common stock were issued to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were awarded as compensation to the Reporting Person for his service as a director of the Company."}],"balance_after":3125,"source":{"system":"sec-edgar","filing":"0001104659-23-018755","document":"tm236233-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923018755/tm236233-2_5seq1.xml","form_type":"5"}},{"id":2054445,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option","published_at":"2023-01-13T18:00:33.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":1.41,"value":14100.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the reporting person on January 3, 2023, pursuant to the Issuer's Amended and Restated Stock Incentive Plan. The stock options vest respect to 2,500 shares on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023."}],"balance_after":23525,"derivative":{"exercise_price":1.41,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-23-003747","document":"tm233286-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465923003747/tm233286-5_4seq1.xml","form_type":"4"}},{"id":2397181,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options","published_at":"2022-02-14T20:30:32.000Z","date":"2021-07-30","kind":"grant","acquired":true,"shares":13525,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each non-qualified stock option (\"NSO\") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the \"Company\") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the \"NSO Agreement\") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The NSOs were awarded as compensation to the Reporting Person for his service as a director of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each non-qualified stock option (\"NSO\") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the \"Company\") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the \"NSO Agreement\") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each non-qualified stock option (\"NSO\") represents a contingent right to receive one share of common stock upon exercise subject to the terms and conditions set forth in the award of such NSOs by iSpecimen Inc. (the \"Company\") to the Reporting Person pursuant to a Nonqualified Stock Option Award Agreement (the \"NSO Agreement\") under the iSpecimen Inc. 2021 Amended and Restated Stock Incentive Plan, as amended. The NSOs has a vesting term of three years with a one-year cliff (i.e. 33.33% of the NSOs vest on June 21, 2022, and the rest of the NSOs vest in equal quarterly installments on September 21, 2022 and each December 21, March 21, June 21 and September 21 until June 21, 2024), subject to the terms and conditions set forth in the NSO Agreement."}],"balance_after":13525,"derivative":{"exercise_price":8,"underlying":"Common Stock","underlying_shares":13525},"source":{"system":"sec-edgar","filing":"0001104659-22-022568","document":"tm226491-6_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465922022568/tm226491-6_5seq1.xml","form_type":"5"}},{"id":2397180,"issuer":{"id":8372,"kind":"organization","name":"iSpecimen Inc."},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T20:30:32.000Z","date":"2021-07-30","kind":"grant","acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares underlying certain restricted stock units (\"RSUs\"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the \"RSU Agreement\"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on September 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying certain restricted stock units (\"RSUs\"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the \"RSU Agreement\"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on September 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs were awarded as compensation to the Reporting Person for his service as the director of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents shares underlying certain restricted stock units (\"RSUs\"), each of which is a contingent right to receive one share of common stock at settlement subject to the terms and conditions set forth in the award of such RSUs by the Company to the Reporting Person pursuant to a Restricted Stock Unit Award Agreement (the \"RSU Agreement\"). The RSUs vest in four equal installments on September 21, 2021, December 21, 2021, March 21, 2022 and June 21, 2022, subject to the terms and conditions set forth in the RSU Agreement. 625 RSUs and 625 RSUs were settled for shares of common stock on September 30, 2021 and December 31, 2021, respectively, and the Reporting Person was issued 1,250 shares of common stock."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001104659-22-022568","document":"tm226491-6_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1558569/000110465922022568/tm226491-6_5seq1.xml","form_type":"5"}},{"id":3310574,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (right to buy)","published_at":"2020-01-15T19:11:20.000Z","date":"2020-01-13","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant."}],"balance_after":60000,"derivative":{"exercise_price":8.39,"expiration_date":"2030-01-12","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001683168-20-000157","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000168316820000157/ownership.xml","form_type":"4"}},{"id":3455076,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-07-26T16:01:13.000Z","date":"2019-07-24","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001596771-19-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677119000080/primary_doc.xml","form_type":"4"}},{"id":3918216,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-05-24T16:31:57.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was approved by the board of directors of the issuer on May 1, 2018, subject to stockholder approval of an amendment to the equity incentive plan under which the option was granted. The issuer's stockholders approved such amendment on May 22, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50,000 shares underlying the option will vest if and when the issuer's common stock achieves a specified volume weighted average closing price for 30 consecutive days on or before December 31, 2019. 50,000 remaining shares underlying the option award are subject to a performance condition and will vest on the date that the first patient in the first Phase 3 clinical trial in a non-orphan indication receives the first dose of gemcabene if such event occurs on or before December 31, 2019. The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock."}],"balance_after":50000,"derivative":{"exercise_price":5.56,"expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001596771-18-000061","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677118000061/primary_doc.xml","form_type":"4"}},{"id":3918215,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-05-24T16:31:57.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was approved by the board of directors of the issuer on May 1, 2018, subject to stockholder approval of an amendment to the equity incentive plan under which the option was granted. The issuer's stockholders approved such amendment on May 22, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date. The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock."}],"balance_after":50000,"derivative":{"exercise_price":5.56,"expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001596771-18-000061","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677118000061/primary_doc.xml","form_type":"4"}},{"id":3946867,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-05-03T16:32:51.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date.  The option includes an early exercise provision, subject to the issuer's right of repurchase with respect to any unvested shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person ceased to be a manager of Excel Venture Fund II, L.P. on May 1, 2018 and will no longer report beneficial ownership of the issuer's securities owned by such entity."}],"balance_after":150000,"derivative":{"exercise_price":5.56,"expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001596771-18-000053","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677118000053/primary_doc.xml","form_type":"4"}},{"id":4065527,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2018-02-12T16:31:00.000Z","date":"2018-02-08","kind":"purchase","acquired":true,"shares":71429,"price":7,"value":500003.0,"ownership":{"direct":false,"nature":"Held by Excel Venture Fund II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased in a confidentially marketed public offering pursuant to an Underwriting Agreement. The offering closed on February 12, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":930252,"source":{"system":"sec-edgar","filing":"0001596771-18-000019","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677118000019/primary_doc.xml","form_type":"4"}},{"id":4084628,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-30T16:06:31.000Z","date":"2018-01-29","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal consecutive monthly installments on the last day of each month, commencing on the grant date, subject to acceleration upon the appointment of a permanent President and Chief Executive Officer."}],"balance_after":60000,"derivative":{"exercise_price":10.44,"expiration_date":"2028-01-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001596771-18-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677118000009/primary_doc.xml","form_type":"4"}},{"id":4261750,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1083119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":108998},"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4261749,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1153606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":116091},"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4261748,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-2 Preferred Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":1329993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":133842},"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4261747,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":5934050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":597167},"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4261746,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":60000,"price":15,"value":900000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":1016100,"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4261745,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":174555,"kind":"organization","name":"EXCEL MEDICAL FUND LP","position":1,"cik":"0001428044","reported_name":"EXCEL MEDICAL FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":2,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174556,"kind":"person","name":"Blume Frederick R.","position":3,"cik":"0001572066","reported_name":"Blume Frederick R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174557,"kind":"person","name":"Enriquez Juan","position":4,"cik":"0001572090","reported_name":"Enriquez Juan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174558,"kind":"organization","name":"Excel Medical Ventures, LLC","position":5,"cik":"0001571999","reported_name":"Excel Medical Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-06T18:16:08.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":956100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical\nVentures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of\nthe shares except to the extent of any pecuniary interest therein."}],"balance_after":956100,"source":{"system":"sec-edgar","filing":"0000899243-17-018010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428044/000089924317018010/doc4.xml","form_type":"4"}},{"id":4299442,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-31T16:25:03.000Z","date":"2017-05-30","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal consecutive monthly increments, so that all of the shares will be vested on the one year anniversary of the date of grant, subject to acceleration upon the appointment of a permanent President and Chief Executive Officer."}],"balance_after":60000,"derivative":{"exercise_price":10.26,"expiration_date":"2027-05-29","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001596771-17-000041","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677117000041/primary_doc.xml","form_type":"4"}},{"id":4385823,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2017-03-14T17:33:07.000Z","date":"2017-03-10","kind":"purchase","acquired":true,"shares":39599,"price":9.47,"value":375002.53,"ownership":{"direct":false,"nature":"Held by Excel Venture Fund II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":39599,"derivative":{"exercise_price":10.4,"exercise_date":"2017-03-10","expiration_date":"2022-03-15","underlying":"Common Stock","underlying_shares":39599},"source":{"system":"sec-edgar","filing":"0001596771-17-000020","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677117000020/primary_doc.xml","form_type":"4"}},{"id":4385822,"issuer":{"id":7947,"kind":"organization","name":"MetaVia Inc.","symbol":"MTVA"},"owners":[{"id":90806,"kind":"person","name":"Gullans Steven R. Ph.D.","position":1,"cik":"0001571997","reported_name":"Gullans Steven R. Ph.D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-14T17:33:07.000Z","date":"2017-03-10","kind":"purchase","acquired":true,"shares":52798,"price":9.47,"value":499997.06,"ownership":{"direct":false,"nature":"Held by Excel Venture Fund II, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":858823,"source":{"system":"sec-edgar","filing":"0001596771-17-000020","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571997/000159677117000020/primary_doc.xml","form_type":"4"}}]}